Trade Allakos Inc. - ALLK CFD

Add to favourite

0.21

2.32%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data

Trading сonditions

Spread

0.04

Long position overnight fee

-0.023679%

Short position overnight fee

0.001457%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

5.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	0.2152
Open	0.2244
1-Year Change	-82.19%
Day's Range	0.2053 - 0.2244

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Mar 28, 2025	0.2102	-0.0034	-1.59%	0.2136	0.2244	0.2053
Mar 27, 2025	0.2152	-0.0027	-1.24%	0.2179	0.2179	0.2102
Mar 26, 2025	0.2104	-0.0042	-1.96%	0.2146	0.2154	0.2063
Mar 25, 2025	0.2187	-0.0049	-2.19%	0.2236	0.2250	0.2149
Mar 24, 2025	0.2251	-0.0092	-3.93%	0.2343	0.2343	0.2180
Mar 21, 2025	0.2279	-0.0037	-1.60%	0.2316	0.2330	0.2246
Mar 20, 2025	0.2312	-0.0051	-2.16%	0.2363	0.2400	0.2290
Mar 19, 2025	0.2358	0.0040	1.73%	0.2318	0.2368	0.2303
Mar 18, 2025	0.2356	0.0002	0.08%	0.2354	0.2357	0.2335
Mar 7, 2025	0.2404	0.0000	0.00%	0.2404	0.2404	0.2404
Feb 27, 2025	0.2617	0.0000	0.00%	0.2617	0.2617	0.2617
Feb 24, 2025	0.2691	-0.0051	-1.86%	0.2742	0.2847	0.2531
Feb 21, 2025	0.2663	-0.0012	-0.45%	0.2675	0.2708	0.2599
Feb 20, 2025	0.2713	0.0048	1.80%	0.2665	0.2788	0.2651
Feb 19, 2025	0.2740	-0.0103	-3.62%	0.2843	0.2851	0.2658
Feb 18, 2025	0.2922	0.0136	4.88%	0.2786	0.3037	0.2718
Feb 14, 2025	0.2943	0.0281	10.56%	0.2662	0.2987	0.2571
Feb 13, 2025	0.2770	0.0323	13.20%	0.2447	0.2775	0.2371
Feb 12, 2025	0.2452	0.0028	1.16%	0.2424	0.2470	0.2351
Jan 31, 2025	0.2200	0.0000	0.00%	0.2200	0.2400	0.2200

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

1:1
2:1
3:1
5:1
10:1
20:1

Leverage

20:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Allakos Inc. Company profile

About Allakos Inc

Allakos Inc. is a clinical stage biotechnology company. The Company is developing therapeutics, which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Its advanced antibodies are lirentelimab (AK002) and AK006. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are widely distributed in the body and play a central role in the inflammatory response. It is developing AK002 for the treatment of eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic duodenitis (EoD), atopic dermatitis, chronic spontaneous urticaria and additional indications. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It also developed a formulation of lirentelimab for subcutaneous (SC) administration. The Company is also developing additional antibodies targeting inhibitory receptors expressed on key disease-driving immune cells.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Allakos Inc revenues was not reported. Net loss increased 76% to $269.9M. Higher net loss reflects Research and Development - Balancing increase of 88% to $176.5M (expense), General and Administrative - Balancing increase of 49% to $44.2M (expense), Stock-based Compensation in SGA increase of 42% to $31M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$3.10 to -$5.01.

Industry:

Bio Therapeutic Drugs

825 Industrial Road
Suite 500
SAN CARLOS
CALIFORNIA 94070
US